Home > Insider Trading > Filing (0001237899-13-000010)

Filing Details

Accession Number:: 0001237899-13-000010
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-01-04 10:00:56
Reporting Period:: 2013-01-02

Filing Date:: 2013-01-04
Accepted Time:: 2013-01-04 10:00:56
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
872589	Regeneron Pharmaceuticals Inc	REGN	Pharmaceutical Preparations (2834)	133444607

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1377247	Peter Powchik	777 Old Saw Mill River Road Tarrytown NY 10591	Svp Clin Devel & Reg Affairs	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2013-01-02	30,000	$21.25	44,990	No	4	M	Direct
Common Stock	Disposition	2013-01-02	3,584	$177.82	41,406	No	4	F	Direct
Common Stock	Disposition	2013-01-02	12,830	$177.82	28,576	No	4	F	Direct
Common Stock	Disposition	2013-01-03	786	$180.83	27,790	No	4	S	Direct
Common Stock	Disposition	2013-01-03	6,200	$181.51	21,590	No	4	S	Direct
Common Stock	Disposition	2013-01-03	2,300	$182.29	19,290	No	4	S	Direct
Common Stock	Disposition	2013-01-03	4,300	$183.10	14,990	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	F	Direct
No	4	F	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2013-01-02	30,000	$0.00	30,000	$21.25

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
295		2019-12-18	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,532	Indirect	By 401(k) Plan

Footnotes

Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
Represents volume-weighted average price of sales of 786 shares of Company stock on January 3, 2013 at prices ranging from $180.44 to $180.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 3, 2013 at each separate price.
Represents volume-weighted average price of sales of 6,200 shares of Company stock on January 3, 2013 at prices ranging from $181.00 to $181.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 3, 2013 at each separate price.
Represents volume-weighted average price of sales of 2,300 shares of Company stock on January 3, 2013 at prices ranging from $182.03 to $182.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 3, 2013 at each separate price.
Represents volume-weighted average price of sales of 4,300 shares of Company stock on January 3, 2013 at prices ranging from $183.01 to $180.3.40. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 3, 2013 at each separate price.
The option became exercisable with respect to all shares underlying the option on December 31, 2012, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2012.
Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.